# Survey on EU Mechanisms Impacting Accessibility of Medicinal Products

*Dear Respondent,  
This survey aims to assess the impact of European Union mechanisms on the accessibility and availability of medicinal products across Member States. Your participation is invaluable in providing insights that will inform research and policy recommendations. The survey includes both qualitative and quantitative questions, with options for open-ended responses, closed questions, and rating scales.  
The results of this survey will be used solely for scientific and research purposes. The findings and conclusions derived from the collected data do not represent, in any way, the official position of any institution, governmental organization, or regulatory authority. All responses will be treated with strict confidentiality and used exclusively for academic analysis.  
We kindly request that you complete the survey by responding to all sections. Thank you for your time and valuable input.   
  
Best regards,  
Atanas Toshev  
PhD student at Medical University of Plovdiv, Bulgaria*

## Section 1: Basic Information

1. What is the name of your institution?

2. What is your role within your institution?

3. How many years of experience do you have in the field of medicinal product regulation?

## Section 2: Impact of EU Mechanisms on Accessibility

**\*\*Joint Procurement Agreement (JPA):\*\***

4. Has your country participated in the Joint Procurement Agreement (JPA) for medicinal products? (Yes/No)

5. If yes, which categories of medicines have been procured through the JPA (e.g., vaccines, antibiotics, orphan drugs)?

6. How would you rate the effectiveness of the JPA in improving the accessibility of medicinal products in your country? (Scale: 1 - Not effective to 5 - Very effective)

7. What are the main challenges associated with implementing the JPA? (Open-ended)

**\*\*Advance Purchase Agreements (APAs):\*\***

8. Has your country participated in Advance Purchase Agreements for COVID-19 vaccines? (Yes/No)

9. How have these agreements affected the timing of deliveries and accessibility of vaccines in your country? (Open-ended)

10. Do you believe APAs should be expanded to other categories of medicines? Why or why not? (Open-ended)

**\*\*Forums like Critical Medicines Alliance (CMA):\*\***

11. Is your country a member of the Critical Medicines Alliance or similar organizations? (Yes/No)

12. How would you assess the contribution of such forums in addressing shortages of medicines? (Scale: 1 - No contribution to 5 - Significant contribution)

13. What new initiatives or mechanisms would you propose within such forums? (Open-ended)

## Section 3: National Challenges and Practices

14. What are the main challenges in ensuring access to essential medicines in your country? (Select all that apply):

- Supply shortages  
 - Logistics issues  
 - Financial constraints  
 - Regulatory barriers  
 - Other (please specify):

15. Do you believe the existing EU mechanisms are sufficient to overcome these challenges? (Yes/No) Please justify your answer.

## Section 4: Satisfaction with EU Collaboration

16. How would you rate the level of collaboration between your country and the EU in the field of availability of medicinal products in your country? (Scale: 1 - Very poor to 5 - Very good)

17. Are there areas where you would like to see enhanced collaboration or support from the EU? (Open-ended)

## Section 5: Suggestions and Recommendations

18. What additional mechanisms or policies would you recommend to the EU to improve the accessibility of medicinal products? (Open-ended)

19. Would you support stricter centralization of medicinal product procurement at the EU level? Why or why not? (Open-ended)

20. What is the most significant improvement your institution has observed since the implementation of EU mechanisms? (Open-ended)

## Section 6: Additional Comments

21. Do you have any other comments or recommendations regarding the topic of this survey? (Open-ended)